The role of MDM2 oncogene in the regulation of tumour growth
Background
A wide variety of oncogenes and tumour suppressor genes are responsible for regulating cell proliferation and development. It has been known for decades that mutations in these genes give a predisposition to cancer. Murine double minute 2 (MDM2) encodes for MDM2 protein, a nuclear phosphoprotein that binds and inhibits transactivation by tumour protein p53, as part of an autoregulatory negative feedback loop (Freedman, D.A., et al. 1999). MDM2 gene is classified as an oncogene as it is widely overexpressed in a variety of human tumours.
MDM2 has several domains that are conserved between species, ranging from humans to zebrafish (Momand, J., et al. 1998). The amino-terminus of MDM2 encodes for the p53 negative regulator site. This site is necessary and sufficient for interaction with p53 tumor suppressor protein and inhibition of its transcriptional activation function. This is achieved via the interaction with the N-terminal p53 binding domain to promote p53 ubiquitylation, which targets p53 protein for proteasomal degradation (Chen J., et al. 1993). The primary function of MDM2 protein is to act as a repressor of p53 through this mechanism.
P53 is a well-studied tumour suppressor protein that is responsible cell cycle regulation by inducing growth arrest and apoptosis when DNA is damaged. The three major roles of p53 are cell cycle arrest, DNA repair, and programmed cell death (apoptosis)(Freedman, D.A., et al. 1999). P53 functions as a physiological barrier against clonal expansion or mutation accumulation in the genome. The gene also controls and arrest growth of the cells that hyperproliferate when subjected to oncogene activity. P53 repression and inactivation is strongly correlated to about 50% of cancers when knocked out, inactive or mutated in a wide range of mammals (Batinac, T., et al. 2003). P53 mutations typically occur on one allele, but this is usually sufficient for enough damaged genes in cells to escape the p53 surveillance and become immortalized cancer cells at some point.
When DNA is damaged, MDM2 is repressed and allows p53 to stop cell cycle proliferation to repairs. When MDM2 is present, p53 function is inhibited and the cell cycle continues. Thus, MDM2 is also known as an oncogene because an overabundance of MDM2 shuts down p53 completely, thereby compromising its cancer-preventing abilities (Perry M. E., et al. 1993). Although it is well known that MDM2 protein acts on p53, its independent functions and gene regulation are not well defined. A study by Reifenberger et al. (1993) show there has been shown to be MDM2 overexpression but no TP53 mutation indicative that MDM2 overexpression can take the place of inactivating TP53 mutations.
To facilitate transcription of MDM2, recruitment of TRRAP protein to the promoter of MDM2 by p53 is required, as part of the negative feedback loop. TRRAP functions as a transcriptional cofactor that recruits several other actyltransferase complexes, which catalyze the modification and acetylation of histones, associated with the MDM2 promoter (de Graaf, P., et al. 2003). In turn, MDM2 transcription is induced.
Relevance
Overexpression of MDM2 has been correlated in excessive inactivation of tumour suppressor protein p53(Freedman, D.A., et al. 1999). In this way, MDM2 could affect cell cycle regulation, apoptosis and tumorgenesis. MDM2 is overexpressed by gene amplification, increased transcription or enhanced translation. It has been shown to be amplified in a variety of tumours including soft tissue sarcomas, osteosarcomas and gliomas. The highest frequency, about 20%, of MDM2 amplification is found in soft tissue tumours, which includes Ewing’s sarcoma, leiomyosarcomas, lipomas, malignant Schwannomas and many other sarcomas. The second highest frequency of MDM2 amplification had been shown in osteosarcomas at 16% (Isreal, B. et al. 2010). Furthermore, Higher frequency of splice variants lacking p53 binding domain sequences was found in late stage and high grade ovarian and bladder carcinomas (Ladanyi, M., et al. 1993). Understanding how gene regulation of MDM2 occurs and its association with cancers may lead to MDM2 gene targeted therapy for specific cancers.
Research question
While p53 mutation typically occurs in one allele (Li-Fraumeni syndrome), MDM2 regulates all p53 activity through repression. Based on this, my question is whether MDM2 overexpression will allow for cancer cell proliferation and metastasis to happen more readily and efficiently than a single allele p53 mutation.
Hypothesis
Since a p53 mutation occurs on one allele, there is another functional copy of the tumour suppressor gene encoding for a functional tumour supressing protein, therefore there is “half” the normal amount of cell cycle modulation occurring. However, MDM2 overexpression would allow for faster degradation of all p53 proteins. I hypothesize that MDM2 overexpression would have a greater regulatory role in cancer cell proliferation and have greater tumour growth rates.
Materials and Methods
Mouse models:
· For MDM2 overexpression mice: use a p53+/+ and MDM2+/+ mouse strain and create a model with an inducible promoter at an additional transposed MDM2 gene (explained in experimental approach)
· For a p53 mutant mouse: use a p53+/-, MDM2+/+ mouse model.
· For the positive control: use wildtype mice that are p53+/+ and MDM2+/+.
· For the negative control: use p53 knockout mice (p53-/-). MDM2 can be either wildtype or mutated, because without p53, MDM2 has nothing to act upon.
Use 5 replicates of the test mice, and 3 replicates for the control mice. The mouse strains are available at Jackson Laboratory mouse consortium.
Cancer cell lines:
To create mouse glioblastoma cancer cell, use Cre-loxP–controlled lentiviral vectors to generate a mouse glioblastoma multiforme cancerous tumour model as described and done by Marumoto, T., et al (2008). These mice can then be sacrificed and their cancer cells used for tumour injection.
Experimental approach
To create gain of function MDM2 mice, I would use tyrosine site specific recombinase to insert an MDM2 gene with an inducible promoter, in addition to the existing MDM2 gene. Using the Cre-loxP system as described by Anastassiadis et al. (2009), I would flank the transposed MDM2 gene with lox sites for Cre recombination to occur with a CrePBD (progesterone ligand binding domain) promoter in a Fo generation of mice. The PBD is inducible by synthetic anti-progestin RU 486, but not by endogenous progestins, making it a desirable promoter for this experiment. After breeding these mice so recombination can occur (using embryonic stem cell clones that are crossed with this reporter), embryos are screened for complete recombination using B-galactosidase staining (Anastassiadis, K., et al. 2009). These mice display the same phenotype as WT mice in the absence of RU 486, but can show overexpression (gain of function) MDM2 when RU 486 is introduced. I would allow these mice to mature into adulthood.
Inject glioblastoma cancer cells into each mouse model, at the same site in the brain and same quantity. Ensure that the cells are injected in the same layer of the brain, since cancer cells grow more effectively at certain niches, to guarantee that the cells are surrounded by the same type of environment for equal opportunity growth between mice strains. For gain of function MDM2 mice, inject RU 486 to overexpress MDM2 gene transcription prior to cancer cell injection.
Use p53 protein antibodies and MDM2 protein antibodies to bind proteins present, and measure their quantities with immunofluorescence. These antibodies can also show localization of the proteins to ensure MDM2-p53 interaction. I can also check p53 and MDM2 mRNA levels with qt-PCR to measure the difference in gene expression between the mouse strains.
After allowing time for the tumours to grow, mouse models can be sacrificed at the same time and their tumour mass and volumes measured.
Challenges and Sources of Error
The failure to create a gain of function MDM2 gene is a huge problem since this is the basis of the project. Cre-loxp recombination is typically done to make a conditional knock-out mouse, however, it is possible to recombine genes to knock-in the inducible promoter at the MDM2 gene. This may cause other potential problems such as interfering with gene transcription of other genes, Also, Cre-loxp recombination has been known to have some toxic effects on the mice overtime (Anastassiadis, K., et al. 2009), which may contribute to more DNA damage and tumour formation.
There may be biological differences between the mice, which I would try to minimize by using a larger sample size. Furthermore, I can also genotype the p53 and MDM2 gene using DNA sequencing (the whole genome would take too long) to ensure these genes are the same, therefore functioning the same.
Possible outcomes and Discussion
Predicted outcome: the tumour growth rates of overexpressed MDM2 mice are higher than the p53+/- mice.
If this outcome occurs, it would prove that MDM2 is a key oncogene and its repressing effects on p53. This indicates that MDM2 modulates all p53 activity as its repressor and its overexpression allows for cancer cells to proliferate more readily. If this is the case, immunofluorescence should show p53 proteins saturated with MDM2 binding, showing that they are being led to degradation and not preforming their cell cycle regulation duties.
Null outcome: the tumour growth rates between the mice are relatively similar.
If this outcome occurs, it indicates that MDM2 represses p53 at a moderate level, and its overexpression does not affect all p53 activity. This indicates that there may be a threshold for MDM2 activity on p53 and the negative feedback loop between these proteins is sufficient to compensate for the overexpression of MDM2. If this is the case, the p53 and MDM2 protein antibodies should show a proportional amount of MDM2-p53 binding as the positive control WT mice. This way, there is still p53 preforming its cell cycle regulation duties. The additional translated MDM2 may be repressed by some mechanism to prevent them from binding p53.
Although testing MDM2 overexpression mice against p53+/+ wildtype mice would be simpler than against p53+/- mice, I chose the p53 mutant because it would be more relevant for human cancer studies. This is due to the fact that most single inactivating alleles in p53 have been associated with cancer. Furthermore, Li-fraumeni syndrome, an individual born with only one working p53 allele, has a huge predisposition to developing tumours later in life (Batinac, T., et al. 2003). It is already known that MDM2 affects p53, so this experiment helps to illustrate to what effect MDM2 plays a key role. Research typically associates a p53 mutation as the primary cancer causing factor, but this experiment will demonstrate whether MDM2 repression on p53 affects tumour growth more significantly.
Discovering how significant the role of MDM2 oncogene in tumour progression can lead to exciting new gene targeted cancer therapies. The purpose of this experiment is to learn how gene regulation of an oncogene contributes to cancer cell formation, thereby, we can learn how to manipulate gene regulation to slow down or even prevent gliomas and other cancers that MDM2 affects.
References
Anastassiadis, K., Fu, J., Patsch, C., Hu, S., Weidlich, S., Duerschke, K., Buchholz, F., Edenhofer, F., Stewart, A.F., 2009. Dre recombinase, like Cre, is a highly efficient site-specific recombinase in E. coli, mammalian cells and mice. Disease Models & Mechanisms, 2: 508-515.
Batinac, T., Gruber, F., Lipozencic, J., Zamolo-Koncar, G., Stasic, A., & Brajac, I. (2003). Protein p53--structure, function, and possible therapeutic implications. Acta Dermatovenerologica Croatica : ADC / Hrvatsko Dermatolosko Drustvo, 11(4), 225-230.
Chen J., Marechal V. and Levine A. J. .1993. Mapping of the p53 and mdm-2 interaction domains. Molecular Cell Biology, 13: 4107–4114.
de Graaf, P., Little, N.A., Ramos, Y.F., Meulmeester, E., Letteboer, S.J., Jochemsen, A.G. 2003. Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. J. Biol. Chem. 2003, 3: 38315-24.
Freedman, D.A., Wu, L., Levine, A.J. 1999. Functions of the MDM2 oncoprotein. CMLS Cellular and Molecular Life Sciences, 55: 96-107.
Isreal, B. 2010. Shedding Light OnGene Regulation-Causing Gene Regulation. Current Cancer.
Ladanyi, M., Cha, C., Lewis, R. 1993. MDM2 Gene Amplification in Metastatic Osteosarcoma. Cancer Research, 53:16-18.
Marumoto, T., Tashiro, A., Morvinski, D.F., Scadeng, M., Soda, Y., Gage, F.H., Cerma, I.M. 2008. Development of a novel mouse glioma model using lentiviral vectors. Nature Medicine, 15: 110-116.
Momand, J., Jung, D., Wilczynski, S., Niland, J. 1998. The MDM2 gene amplification database. Nucleic Acids Research, 26(15): 3453-3459.
Perry M. E., Piette J., Zawadzki J. A., Harvey D. and Levine A. J. 1993 The mdm-2 gene is induced in response to UV light in a p53-dependent manner. National Academy of Science USA, 90: 11623–11627.
Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E.E., Collins, V.P. 1993. Amplification and Overexpression of the MDM2 Gene in a Subset of Human Malignant Gliomas without p53 Mutations. Cancer Research, 53:2736-2739.